© Reuters. Blueprint up 4% on planned data presentation from early-stage study of BLU-285 in systemic mastocytosis
- Blueprint Medicines (BPMC +3.9%) perks up on lower-than-normal volume in response to its announcement of a data presentation at ASH in December.
- Updated results from a Phase 1 clinical trial assessing BLU-285 in patients with advanced systemic mastocytosis will be presented during the Plenary Scientific Session on December 10, one of only six abstracts chosen.
- Previously: Blueprint’s BLU-285 shows encouraging action in early-stage GIST study (Dec. 1, 2016)
- Now read: Imprimis To Challenge Allergan (NYSE:AGN)’s Restasis With Cheaper Product